PDE5A and endothelial dysfunction: Phosphodiesterase-5 (PDE-5) inhibitors constitute a well-established class of drugs targeting endothelial dysfunction through increased NO-signalling, resulting in relaxation of vascular smooth muscles and vasodilation.8